Prana Biotechnology Limited (NASDAQ:PRAN)
Industry: Healthcare

OFF LIST - 1296 consecutive market days: OFF LIST as of 04/12/2011 Through 11/14/2016

Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.

Current Quote*
Last: $2.121
Change: 0.141
Book: $1.515
Volume: 227,573

As Of: 10/18 15:57 ET
*Quotes delayed by 20min.

Graphs for PRAN

3 Month Graph

6 Month Graph

1 Year Graph